[8-K] Sana Biotechnology, Inc. Reports Material Event
Sana Biotechnology announced it has issued a press release reporting its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The company states the press release is being furnished and not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless explicitly stated. The 8-K lists Exhibit 99.1 and an Inline XBRL cover page, identifies the registrant as an emerging growth company, and is signed by Acting Chief Financial Officer Susan Wyrick. The company trades on Nasdaq under the ticker SANA.
Sana Biotechnology ha comunicato di avere diffuso un comunicato stampa con i risultati finanziari per il trimestre chiuso il 30 giugno 2025, allegato come Exhibit 99.1 al presente Modulo 8鈥慘. La societ脿 precisa che il comunicato 猫 fornito (furnished) e non depositato (filed), pertanto non 猫 soggetto alle responsabilit脿 previste dalla Sezione 18 e non 猫 incorporato per rinvio in altri documenti, salvo espressa indicazione. L'8鈥慘 elenca l'Exhibit 99.1 e una pagina di copertura Inline XBRL, identifica il registrante come societ脿 in rapida crescita (emerging growth company) ed 猫 firmato dalla Chief Financial Officer ad interim Susan Wyrick. La societ脿 猫 quotata al Nasdaq con il simbolo SANA.
Sana Biotechnology anunci贸 que ha emitido un comunicado de prensa con sus resultados financieros del trimestre cerrado el 30 de junio de 2025, adjunto como Exhibit 99.1 a este Formulario 8鈥慘. La compa帽铆a indica que el comunicado se suministra (furnished) y no se presenta oficialmente (filed), por lo que no est谩 sujeto a las responsabilidades de la Secci贸n 18 y no se incorpora por referencia en otros documentos salvo que se indique expresamente. El 8鈥慘 enumera el Exhibit 99.1 y una portada Inline XBRL, identifica al registrante como una emerging growth company y est谩 firmado por la directora financiera interina Susan Wyrick. La compa帽铆a cotiza en Nasdaq con el ticker SANA.
Sana Biotechnology電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 鞁れ爜鞚� 氤搓碃頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堨溂氅�, 頃措嫻 氤措弰鞛愲電� 氤� Form 8鈥慘鞚� Exhibit 99.1搿� 觳秬霅橃柎 鞛堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞚� 氤措弰鞛愲臧� 鞝滌稖(filed)霅� 瓴冹澊 鞎勲媹霛� 鞝滉车(furnished)霅� 瓴冹澊霛缄碃 氚濏榾 Section 18鞐� 霐半ジ 毂呾瀯鞚� 雽�靸侅澊 鞎勲媹氅�, 氇呾嫓鞝侅溂搿� 鞏戈笁霅橃 鞎婋姅 頃� 雼るジ 氍胳劀鞐� 彀胳“搿� 韼胳瀰霅橃 鞎婋姅雼り碃 氇呾嫓頄堨姷雼堧嫟. 頃措嫻 8鈥慘鞐愲姅 Exhibit 99.1瓿� Inline XBRL 旎る矂 韼橃澊歆�臧� 旮办灛霅橃柎 鞛堦碃, 霌彪須岇偓電� emerging growth company搿� 鞁濍硠霅橂┌, 雽�頄� 鞛毂呾瀯鞛�(Acting Chief Financial Officer) Susan Wyrick鞚� 靹滊獏頄堨姷雼堧嫟. 須岇偓電� 雮橃姢雼レ棎 SANA 韹办护搿� 靸侅灔霅橃柎 鞛堨姷雼堧嫟.
Sana Biotechnology a annonc茅 avoir publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025, communiqu茅 qui est joint en tant qu'Exhibit 99.1 au pr茅sent formulaire 8鈥慘. La soci茅t茅 pr茅cise que le communiqu茅 est fourni (furnished) et non d茅pos茅 (filed), de sorte qu'il n'est pas soumis aux responsabilit茅s pr茅vues par la Section 18 et n'est pas incorpor茅 par renvoi dans d'autres dossiers sauf mention expresse. Le 8鈥慘 茅num猫re l'Exhibit 99.1 et une page de couverture Inline XBRL, identifie l'enregistrant comme une emerging growth company et est sign茅 par la directrice financi猫re par int茅rim Susan Wyrick. La soci茅t茅 est cot茅e au Nasdaq sous le symbole SANA.
Sana Biotechnology gab bekannt, eine Pressemitteilung mit den Finanzergebnissen f眉r das zum 30. Juni 2025 endende Quartal ver枚ffentlicht zu haben; diese ist als Exhibit 99.1 diesem Form 8鈥慘 beigef眉gt. Das Unternehmen erkl盲rt, dass die Pressemitteilung zur Verf眉gung gestellt (furnished) und nicht eingereicht (filed) wurde, weshalb sie nicht den Haftungsregelungen der Section 18 unterliegt und nicht per Verweis in andere Einreichungen aufgenommen wird, sofern nicht ausdr眉cklich angegeben. Das 8鈥慘 listet Exhibit 99.1 und eine Inline XBRL-Coverpage auf, bezeichnet den Registranten als emerging growth company und ist von der amtierenden Chief Financial Officer Susan Wyrick unterzeichnet. Das Unternehmen ist an der Nasdaq unter dem Ticker SANA notiert.
- None.
- None.
Insights
TL;DR: Routine earnings release furnished via 8-K; the filing itself contains no financial figures.
The Form 8-K notifies investors that Sana has furnished a press release containing quarterly financial results for the period ended June 30, 2025, but does not include the press release text or financial metrics in this filing. Because the company expressly states the release is furnished, not filed, the disclosure limits Section 18 liability and avoids automatic incorporation by reference into other filings. Investors must consult Exhibit 99.1 for actual revenue, expense, or earnings details.
TL;DR: Disclosure is procedurally standard and governed by "furnished" treatment; governance implications are minimal.
The 8-K follows common practice of furnishing an earnings press release and documenting the exhibit list and signatory. The filing confirms the signatory is the Acting Chief Financial Officer, which is an appropriate officer-level attestation for this type of disclosure. There are no governance actions, restatements, officer departures, or material transactions disclosed in this document itself.
Sana Biotechnology ha comunicato di avere diffuso un comunicato stampa con i risultati finanziari per il trimestre chiuso il 30 giugno 2025, allegato come Exhibit 99.1 al presente Modulo 8鈥慘. La societ脿 precisa che il comunicato 猫 fornito (furnished) e non depositato (filed), pertanto non 猫 soggetto alle responsabilit脿 previste dalla Sezione 18 e non 猫 incorporato per rinvio in altri documenti, salvo espressa indicazione. L'8鈥慘 elenca l'Exhibit 99.1 e una pagina di copertura Inline XBRL, identifica il registrante come societ脿 in rapida crescita (emerging growth company) ed 猫 firmato dalla Chief Financial Officer ad interim Susan Wyrick. La societ脿 猫 quotata al Nasdaq con il simbolo SANA.
Sana Biotechnology anunci贸 que ha emitido un comunicado de prensa con sus resultados financieros del trimestre cerrado el 30 de junio de 2025, adjunto como Exhibit 99.1 a este Formulario 8鈥慘. La compa帽铆a indica que el comunicado se suministra (furnished) y no se presenta oficialmente (filed), por lo que no est谩 sujeto a las responsabilidades de la Secci贸n 18 y no se incorpora por referencia en otros documentos salvo que se indique expresamente. El 8鈥慘 enumera el Exhibit 99.1 y una portada Inline XBRL, identifica al registrante como una emerging growth company y est谩 firmado por la directora financiera interina Susan Wyrick. La compa帽铆a cotiza en Nasdaq con el ticker SANA.
Sana Biotechnology電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 鞁れ爜鞚� 氤搓碃頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堨溂氅�, 頃措嫻 氤措弰鞛愲電� 氤� Form 8鈥慘鞚� Exhibit 99.1搿� 觳秬霅橃柎 鞛堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞚� 氤措弰鞛愲臧� 鞝滌稖(filed)霅� 瓴冹澊 鞎勲媹霛� 鞝滉车(furnished)霅� 瓴冹澊霛缄碃 氚濏榾 Section 18鞐� 霐半ジ 毂呾瀯鞚� 雽�靸侅澊 鞎勲媹氅�, 氇呾嫓鞝侅溂搿� 鞏戈笁霅橃 鞎婋姅 頃� 雼るジ 氍胳劀鞐� 彀胳“搿� 韼胳瀰霅橃 鞎婋姅雼り碃 氇呾嫓頄堨姷雼堧嫟. 頃措嫻 8鈥慘鞐愲姅 Exhibit 99.1瓿� Inline XBRL 旎る矂 韼橃澊歆�臧� 旮办灛霅橃柎 鞛堦碃, 霌彪須岇偓電� emerging growth company搿� 鞁濍硠霅橂┌, 雽�頄� 鞛毂呾瀯鞛�(Acting Chief Financial Officer) Susan Wyrick鞚� 靹滊獏頄堨姷雼堧嫟. 須岇偓電� 雮橃姢雼レ棎 SANA 韹办护搿� 靸侅灔霅橃柎 鞛堨姷雼堧嫟.
Sana Biotechnology a annonc茅 avoir publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025, communiqu茅 qui est joint en tant qu'Exhibit 99.1 au pr茅sent formulaire 8鈥慘. La soci茅t茅 pr茅cise que le communiqu茅 est fourni (furnished) et non d茅pos茅 (filed), de sorte qu'il n'est pas soumis aux responsabilit茅s pr茅vues par la Section 18 et n'est pas incorpor茅 par renvoi dans d'autres dossiers sauf mention expresse. Le 8鈥慘 茅num猫re l'Exhibit 99.1 et une page de couverture Inline XBRL, identifie l'enregistrant comme une emerging growth company et est sign茅 par la directrice financi猫re par int茅rim Susan Wyrick. La soci茅t茅 est cot茅e au Nasdaq sous le symbole SANA.
Sana Biotechnology gab bekannt, eine Pressemitteilung mit den Finanzergebnissen f眉r das zum 30. Juni 2025 endende Quartal ver枚ffentlicht zu haben; diese ist als Exhibit 99.1 diesem Form 8鈥慘 beigef眉gt. Das Unternehmen erkl盲rt, dass die Pressemitteilung zur Verf眉gung gestellt (furnished) und nicht eingereicht (filed) wurde, weshalb sie nicht den Haftungsregelungen der Section 18 unterliegt und nicht per Verweis in andere Einreichungen aufgenommen wird, sofern nicht ausdr眉cklich angegeben. Das 8鈥慘 listet Exhibit 99.1 und eine Inline XBRL-Coverpage auf, bezeichnet den Registranten als emerging growth company und ist von der amtierenden Chief Financial Officer Susan Wyrick unterzeichnet. Das Unternehmen ist an der Nasdaq unter dem Ticker SANA notiert.
FAQ
What did Sana Biotechnology (SANA) disclose in this 8-K?
Is the press release in the 8-K considered "filed" under the Exchange Act?
Who signed the Form 8-K for Sana?
Where is Sana Biotechnology registered and what is its ticker?
Which exhibits are listed in the 8-K?
